研究人员正在开发能够模拟运动生理效应的药物，通过靶向运动相关的激素、酶和分子信号来创造治疗手段1。Pelagos公司和Cambrian Bio等机构已投入相关化合物的开发工作1。佛罗里达大学Thomas Burris实验室设计的药物在动物试验中表现显著，使老鼠的运动里程和距离超过对照组，研究人员戏称其为"无需运动的马拉松老鼠"1。
Cambrian Bio开发的实验性药物ATX-304在6月的报告中显示，可增加肥胖症和前驱糖尿病患者的代谢、减少肝脏和腹部脂肪1。然而，这类药物的开发面临重大挑战——超过90%进入人体试验的治疗方法最终失败1。此外，FDA仅批准药物用于治疗疾病而非增进健康1，这为这类增强性药物的上市设置了监管障碍。由于初步结果前景看好，反兴奋剂机构已主动禁止了这些化合物1。
Researchers are developing pharmaceutical compounds designed to replicate the benefits of exercise by targeting hormones, enzymes, and molecular signals activated during physical activity.1 Organizations including Pelagos and Cambrian Bio are advancing experimental compounds that show promise in early trials, with results demonstrating enhanced endurance, improved metabolism, and reduced fat accumulation in obese patients.1
A laboratory led by Thomas Burris at the University of Florida created a drug that enabled mice to run significantly greater distances than untreated controls, which researchers described as producing "marathon mice without the exercise."1 More recently, in June, Cambrian Bio's experimental compound ATX-304 was reported to increase metabolic rates and decrease both liver and abdominal fat in patients with obesity and prediabetes.1
These therapeutic approaches face substantial obstacles: over 90 percent of treatments entering human trials fail to reach approval.1 Additionally, the FDA approves medications for disease treatment rather than general health enhancement, creating a regulatory framework challenge for drugs targeting healthy individuals seeking fitness benefits.1
The preliminary results have proven sufficiently compelling that anti-doping agencies have proactively banned these compounds to prevent misuse in competitive sports.1
评论
还没有评论，欢迎留下第一条。